THERANEXUS news, videos and press releases
For more news please use our advanced search feature.
THERANEXUS - More news...
THERANEXUS - More news...
- THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2024 AND PRESENTS ITS PROGRESS REPORT
- THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025
- THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS
- THERANEXUS PRESENTS AN UPDATE OF ITS CASH POSITION AND FINANCING HORIZON
- THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE LICENSING AGREEMENT TO COMMERCIALIZE THERANEXUS TX01 FOR TWO RARE NEUROLOGICAL DISORDERS
- Theranexus Presents an Update of its Cash Position and Financing Horizon
- Theranexus and Exeltis (Insud Pharma) Announce Licensing Agreement to Commercialize Theranexus Tx01 for Two Rare Neurological Disorders
- Update on the Theranexus' Batten-1 project in CLN3 Batten's disease
- THERANEXUS ANNOUNCES ITS CASH POSITION AS OF SEPTEMBER 30, 2024
- THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIATRIC FORMULATION IN NIEMANN-PICK TYPE C DISEASE
- THERANEXUS ANNOUNCES FIRST HALF 2024 FINANCIAL RESULTS
- Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
- THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
- Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
- THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT
- Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
- Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
- THERANEXUS ANNOUNCES APPOINTMENT OF MATHIEU CHARVÉRIAT AS BOARD OF DIRECTORS CHAIRMAN
- THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS
- THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023
- Theranexus : Highly Promising 12-month results in the Phase I/II trial of Batten-1
- THERANEXUS ANNOUNCES FIRST HALF 2023 FINANCIAL RESULTS
- Theranexus raises around 3.1 million euros in fundraising
- Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)
- CORRECTION FROM SOURCE: Theranexus and BBDF Win FDA Approval on Efficacy Endpoints for the Phase III Trial to Evaluate Batten-1 in CLN3 Batten Disease
- Theranexus and BBDF win FDA approval on efficacy endpoints for the Phase III trial to evaluate Batten-1 in CLN3 Batten disease
- Theranexus and BBDF Win FDA Approval on Efficacy Endpoints for the Phase III Trial to Evaluate Batten-1 in CLN3 Batten Disease
- THERANEXUS PUBLISHES ITS 2022 FULL-YEAR RESULTS AND PRESENTS AN UPDATE ON ITS PROGRAMS
- THERANEXUS, BBDF AND CARDIFF UNIVERSITY PRESENT THEIR NOVEL RESEARCH ON BATTEN-1 AND BATTEN DISEASE AT WORLDSYMPOSIUM 2023
- AISTROSIGHT: NEW JOINT PROJECT TEAM BETWEEN THERANEXUS, INRIA, CLAUDE BERNARD UNIVERSITY LYON 1 AND HOSPICES CIVILS DE LYON TARGETING RARE NEUROLOGICAL DISEASES
